为孤儿药提供医疗信息

S. Turbeville, D. A. Wells, C. Hornfeldt
{"title":"为孤儿药提供医疗信息","authors":"S. Turbeville, D. A. Wells, C. Hornfeldt","doi":"10.1177/0092861511427696","DOIUrl":null,"url":null,"abstract":"Medical information departments are responsible for providing information regarding the drugs the company manufactures and the diseases these drugs treat. The medical information departments of orphan drug manufacturers face unique challenges. Although they receive fewer inquiries, those received usually require sophisticated and time-consuming responses, often based on unpublished information and with greater reliance on rare disease experts. Worldwide distribution results in interactions with non-English-speaking individuals and requires familiarity with international legal requirements. Orphan drug medical information staff has greater visibility and is more likely to be contacted regarding adverse events and assistance for investigator-initiated clinical studies. As primary sources of information for patients, they need to be familiar with patient advocacy groups, clinical trial enrollment, and sources of unapproved medications such as expanded access programs. The ideal orphan drug medical information department is staffed with specialized health care professionals with advanced training dedicated to 1 or 2 orphan drug products.","PeriodicalId":391574,"journal":{"name":"Drug information journal : DIJ / Drug Information Association","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Providing Medical Information for Orphan Drugs\",\"authors\":\"S. Turbeville, D. A. Wells, C. Hornfeldt\",\"doi\":\"10.1177/0092861511427696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Medical information departments are responsible for providing information regarding the drugs the company manufactures and the diseases these drugs treat. The medical information departments of orphan drug manufacturers face unique challenges. Although they receive fewer inquiries, those received usually require sophisticated and time-consuming responses, often based on unpublished information and with greater reliance on rare disease experts. Worldwide distribution results in interactions with non-English-speaking individuals and requires familiarity with international legal requirements. Orphan drug medical information staff has greater visibility and is more likely to be contacted regarding adverse events and assistance for investigator-initiated clinical studies. As primary sources of information for patients, they need to be familiar with patient advocacy groups, clinical trial enrollment, and sources of unapproved medications such as expanded access programs. The ideal orphan drug medical information department is staffed with specialized health care professionals with advanced training dedicated to 1 or 2 orphan drug products.\",\"PeriodicalId\":391574,\"journal\":{\"name\":\"Drug information journal : DIJ / Drug Information Association\",\"volume\":\"30 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug information journal : DIJ / Drug Information Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/0092861511427696\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug information journal : DIJ / Drug Information Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0092861511427696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

医疗信息部门负责提供公司生产的药品和这些药品治疗的疾病的信息。孤儿药生产企业的医疗信息部门面临着独特的挑战。虽然他们收到的咨询较少,但收到的咨询通常需要复杂而耗时的答复,往往基于未发表的信息,更多地依赖于罕见疾病专家。全球分布导致与非英语人士的互动,并要求熟悉国际法律要求。孤儿药医疗信息工作人员具有更高的可见度,并且更有可能就不良事件和对研究者发起的临床研究的协助进行联系。作为患者的主要信息来源,他们需要熟悉患者倡导团体、临床试验登记和未经批准的药物来源,如扩大获取计划。理想的孤儿药医疗信息部配备有受过高级培训的专门的医疗保健专业人员,专门负责1或2种孤儿药产品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Providing Medical Information for Orphan Drugs
Medical information departments are responsible for providing information regarding the drugs the company manufactures and the diseases these drugs treat. The medical information departments of orphan drug manufacturers face unique challenges. Although they receive fewer inquiries, those received usually require sophisticated and time-consuming responses, often based on unpublished information and with greater reliance on rare disease experts. Worldwide distribution results in interactions with non-English-speaking individuals and requires familiarity with international legal requirements. Orphan drug medical information staff has greater visibility and is more likely to be contacted regarding adverse events and assistance for investigator-initiated clinical studies. As primary sources of information for patients, they need to be familiar with patient advocacy groups, clinical trial enrollment, and sources of unapproved medications such as expanded access programs. The ideal orphan drug medical information department is staffed with specialized health care professionals with advanced training dedicated to 1 or 2 orphan drug products.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信